GIP, also known as glucose-dependent insulinotropic peptide, has been shown to suppress gastrin stimulated gastric acid secretion and delay GI transit in animal models, suggesting its potential contribution to FD symptoms via both endocrine and motility pathway [31, , -34]. This evidence concerns the gene GAST and Fabry disease.